Skip to main content
Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Moderna's RSV Price Gamble: Doubling Down on mRNA as Rivals Dominate Market

Summary by WebProNews
Moderna roughly doubled the list price of its mRESVIA RSV vaccine, sending shares higher despite lagging sales against GSK and Pfizer rivals. A new EU contract for up to 24 million doses offers hope, but payer pushback and clinical differentiation will decide if the strategy succeeds.

1 Articles

WebProNewsWebProNews
Center

Moderna's RSV Price Gamble: Doubling Down on mRNA as Rivals Dominate Market

Moderna roughly doubled the list price of its mRESVIA RSV vaccine, sending shares higher despite lagging sales against GSK and Pfizer rivals. A new EU contract for up to 24 million doses offers hope, but payer pushback and clinical differentiation will decide if the strategy succeeds.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

WebProNews broke the news on Tuesday, September 8, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Moderna icon

Moderna

Vaccines icon

Vaccines

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal